Pliant Therapeutics heads into its May 13 earnings report with short sellers retreating — yet the borrow market flashing an unusual signal in the opposite direction.
Short interest has eased materially over the past month. It now runs at 5.7% of the free float, down roughly 9% from a month ago and shedding nearly 2% in the past week alone. That sustained reduction suggests bears are not piling into the print. The ORTEX short score of 46.5 — mid-range and broadly stable across the past two weeks — reinforces the picture of a market that is neither aggressively positioned short nor scrambling to cover.
The cost to borrow tells a sharply different story. Borrowing costs have exploded from near-zero to 4.1% APR in the space of a week — a rise of more than 650% in seven days — after spending most of April below 0.7%. That spike is the single sharpest near-term move in the data. It does not yet point to a squeeze, given that borrow availability remains ample and the overall short book is shrinking, but it does signal that demand for new short positions has jumped just as the company approaches its announcement. Availability is still well above the point of stress, so this looks more like incremental hedging than a structural tightening.
Options positioning leans heavily toward protection. The put/call ratio runs at 2.34 — roughly in line with its 20-day average of 2.32, suggesting the skew toward puts is not a sudden shift but a sustained baseline posture. PLRX options have traded near the top of their 52-week put/call range for most of the past month, peaking at 2.87 in mid-April before easing slightly. The stock itself has drifted lower, down 6.25% over the past month to close at $1.20, clawing back less than 1% on the week.
The analytical community is cautious but divided. The bear case centres on pipeline concentration risk — the company's fate is tightly bound to PLN-101095 — and persistent financial strain, with an updated cash position and rising share count putting pressure on the balance sheet. Bulls point to promising Phase I efficacy signals, particularly IFN-γ responses in solid tumour trials, and a differentiated integrin-targeted platform that could open multiple indications. The most recent analyst changes on record — from Canaccord and Piper Sandler in mid-March — both maintained ratings while trimming targets to $3.00, implying more than 150% upside to current levels. That gap between target and price is notable, though the analyst data is now roughly two months old. JPMorgan downgraded to Underweight in October 2025 and has not moved since; the spread between that call and Piper's Overweight rating captures the debate in a single comparison.
The May 13 print will test whether PLN-101095's clinical trajectory can begin to justify the distance between where analysts set their targets and where the market has pushed the stock.
See the live data behind this article on ORTEX.
Open PLRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
